ALDX NASDAQ
Aldeyra Therapeutics, Inc.
1W: -4.2%
1M: -6.5%
3M: -67.9%
YTD: -66.0%
1Y: -32.6%
3Y: -84.1%
5Y: -86.9%
$1.55
-0.04 (-2.52%)
Weekly Expected Move ±7.0%
$1
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
2 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (75)
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
ALDX Deadline Alert: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline
ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After FDA Issued A CRL Indicating Insufficient Efficacy: Levi & Korsinsky
ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026
ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Disregarded FDA Requirements: Levi & Korsinsky
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
ALDX Shareholder Alert: May 29, 2026 Lead Plaintiff Deadline in Aldeyra Therapeutics, Inc. Securities Class Action - Contact The Gross Law Firm
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
ADLX Stockholders Have Rights – If You Lost Money Investing in Aldeyra Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
ALDX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Aldeyra Therapeutics Investors - Contact Kirby McInerney LLP by May 29, 2026
ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Down 14.6% in March
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
ALDX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aldeyra Therapeutics, Inc. Securities Lawsuit — The Gross Law Firm
ROSEN, A LEADING AND RANKED FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky
ADLX Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Aldeyra Therapeutics, Inc. Class Action Lawsuit
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Shareholders who lost money in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Should Contact Wolf Haldenstein Immediately
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. (ALDX)
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Aldeyra Therapeutics, Inc. (ALDX) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
$ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Sees Large Increase in Short Interest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
Aldeyra Therapeutics (NASDAQ:ALDX) Director Buys $98,000.00 in Stock
ALDX Investor News: If You Have Suffered Losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
FY2026 Earnings Forecast for ALDX Issued By HC Wainwright
12 Health Care Stocks Moving In Thursday's Intraday Session
What's Going On With Aldeyra Therapeutics Stock On Thursday?
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Aldeyra Therapeutics Sees Unusually Large Options Volume (NASDAQ:ALDX)
$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
12 Health Care Stocks Moving In Tuesday's Intraday Session
FDA Rejects Aldeyra's Dry Eye Drug For Third Time, Stock Crashes 68%
Crude Oil Gains Around 2%; Elbit Systems Shares Jump On Upbeat Earnings
Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Nasdaq Surges Over 100 Points; Academy Sports And Outdoors Posts Downbeat Earnings
Aldeyra plunges as FDA rejects dry eye disease therapy
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Catalyst Watch: Nvidia's GTC Conference, FOMC meeting, Okta event, and triple-witching day
HC Wainwright Has Optimistic Outlook of ALDX Q1 Earnings
What is HC Wainwright’s Estimate for ALDX FY2027 Earnings?
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Below 200-Day Moving Average – Here’s What Happened
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know
Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year?
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 50 Day Moving Average – Time to Sell?
Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst
Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease